• We participate in phase 1 studies (initial studies) to evaluate the safety and effectiveness of new antiretroviral drugs.
• We study the interactions of new antiretroviral drugs with other treatments.
• We make progress in our knowledge of the resistances that can emerge with the use of new antiretrovirals.

We promote studies and conduct clinical trials with therapeutic vaccines (to treat people already infected with HIV) and preventive vaccines (to prevent infection). We also study viral reservoirs, i.e., where the virus hides in the body, in order to be able to access it and eliminate it.

Currently in our environment, more than 50% of people with HIV are over 50 years old. For this reason, we study the diagnosis of pathologies specific to ageing and other related conditions from a social, psychological, mental and functional point of view. In addition, we provide knowledge to tackle the side effects of prolonged treatments over time.

Currently, thanks to the effectiveness of existing treatments, there are few people with HIV who are also infected with the Hepatitis C virus. We focus on the study of fatty liver, a liver pathology that is very common among HIV patients, especially as their age increases.

A high percentage of people with HIV are co-infected with the human papilloma virus (HPV). Since 2005, the Foundation has offered routine check-ups for the detection, diagnosis, follow-up and treatment of lesions caused by the human papilloma virus in both men and women with HIV

Pre-exposure prophylaxis (PrEP) is an HIV prevention strategy that involves the administration of antiretroviral drugs to HIV-negative people to reduce their risk of becoming infected.

We work in collaboration with the BCN Checkpoint and BCN Prep·Point community centre, in the heart of Barcelona, to reach a population of more than 6,000 people who are regularly tested for HIV and other sexually transmitted infections (STIs).

Although good nutrition has no impact on the prevention of HIV or the cure of AIDS, it helps to manage patients and improve their quality of life.

The diet line of action works closely with the ageing area by assessing nutritional status in cohorts made up of older people with HIV and collaborates in the Foundation’s projects for other lines of research.

Neurocognitive deterioration: we work on the early detection and treatment of the main effects of HIV and the impact of antiretrovirals on the central nervous system, creating strategies to slow down and improve neurocognitive deterioration.

Emotional well-being: we identify the main factors that affect the quality of life of people with HIV, such as those related to living with the virus for many years.